Biomarker Testing for Advanced Lung Cancer-What is Biomarker Testing for Advanced Lung Cancer and Why is it Important?

What is Biomarker Testing for Advanced Lung Cancer and Why is it Important?

Video Transcription

Video Summary

In this webinar, Dr. Bruce Johnson discusses the importance of biomarker testing for advanced lung cancer. He begins by introducing the different mutations and chromosomal rearrangements for which there are targeted therapies available, such as EGFR, ALK, ROS1, BRAF, and PD-L1. He emphasizes the significance of identifying these biomarkers and how it can transform the care of patients with lung cancer. Dr. Johnson also presents case studies to illustrate the effectiveness of targeted therapies in achieving long-term responses and improving survival rates. He highlights the lower toxicity profile of these targeted therapies compared to traditional chemotherapy, making them suitable for a wider range of patients, including the elderly. Dr. Johnson urges the importance of biomarker testing in all patients, regardless of clinical characteristics or smoking history. He also emphasizes the need for timely testing and increased uptake of biomarker testing to improve patient outcomes.

Keywords

biomarker testing

advanced lung cancer

targeted therapies

EGFR

ALK

ROS1

BRAF

PD-L1

patient outcomes